Filtered By:
Drug: Beta-Blockers

This page shows you your search results in order of relevance. This is page number 3.

Order by Relevance | Date

Total 494 results found since Jan 2013.

First-line drugs inhibiting the renin angiotensin system versus other first-line antihypertensive drug classes for hypertension.
CONCLUSIONS: We found predominantly moderate quality evidence that all-cause mortality is similar when first-line RAS inhibitors are compared to other first-line antihypertensive agents. First-line thiazides caused less HF and stroke than first-line RAS inhibitors. The quality of the evidence comparing first-line beta-blockers and first-line RAS inhibitors was low and the lower risk of total CV events and stroke seen with RAS inhibitors may change with the publication of additional trials. Compared with first-line CCBs, first-line RAS inhibitors reduced HF but increased stroke. The magnitude of the reduction in HF exceeded...
Source: Cochrane Database of Systematic Reviews - January 11, 2015 Category: Journals (General) Authors: Xue H, Lu Z, Tang WL, Pang LW, Wang GM, Wong GW, Wright JM Tags: Cochrane Database Syst Rev Source Type: research

Socioeconomic factors and use of secondary preventive therapies for cardiovascular diseases in South Asia: The PURE study
Conclusion The use of secondary preventive drug therapies in patients with known CHD or stroke in South Asia is low with over 80% receiving none of the effective drug treatments. Low household wealth is the most important determinant.
Source: European Journal of Preventive Cardiology - September 11, 2015 Category: Cardiology Authors: Gupta, R., Islam, S., Mony, P., Kutty, V. R., Mohan, V., Kumar, R., Thakur, J., Shankar, V. K., Mohan, D., Vijayakumar, K., Rahman, O., Yusuf, R., Iqbal, R., Shahid, M., Mohan, I., Rangarajan, S., Teo, K. K., Yusuf, S. Tags: Original scientific papers Source Type: research

The Role of Beta-Blockers in the Treatment of Hypertension.
CONCLUSIONS AND RELEVANCE: Primary/essential hypertension in younger/middle-age is underpinned by high sympathetic nerve activity. In this age-group high resting heart rates and high plasma norepinephrine levels (independent of blood pressure) are linked to premature cardiovascular events and death. Thus, anti-hypertensive agents that increase sympathetic nerve activity ie diuretics, dihydropyridine calcium blockers, and ARBs, are inappropriate first-line choices in this younger age-group. Beta-blockers perform well vs randomised placebo and other antihypertensive agents regarding reduced risk of death/stroke/myocardial in...
Source: Advances in Experimental Medicine and Biology - December 14, 2016 Category: Research Tags: Adv Exp Med Biol Source Type: research

First-line drugs for hypertension.
CONCLUSIONS: First-line low-dose thiazides reduced all morbidity and mortality outcomes in adult patients with moderate to severe primary hypertension. First-line ACE inhibitors and calcium channel blockers may be similarly effective, but the evidence was of lower quality. First-line high-dose thiazides and first-line beta-blockers were inferior to first-line low-dose thiazides. PMID: 29667175 [PubMed - as supplied by publisher]
Source: Cochrane Database of Systematic Reviews - April 18, 2018 Category: General Medicine Authors: Wright JM, Musini VM, Gill R Tags: Cochrane Database Syst Rev Source Type: research

Effects of blood pressure lowering on outcome incidence in hypertension: 4. Effects of various classes of antihypertensive drugs – Overview and meta-analyses
Conclusion: BP lowering by all classes of antihypertensive drugs is accompanied by significant reductions of stroke and major cardiovascular events. This supports the concept that reduction of these events is because of BP lowering per se rather than specific drug properties. However, evidence of risk reduction of other events and particularly mortality was obtained so far with some drug classes only. As a result of marked differences in the trial design, total cardiovascular risk, SBP/DBP differences and statistical power, comparisons of meta-analyses of different drug-specific placebo-controlled RCTs appear unwarranted.
Source: Journal of Hypertension - January 6, 2015 Category: Cardiology Tags: Reviews and Meta-Analyses Source Type: research

A Serious Diagnosis Lacking Common Symptoms
​BY JENNIFER TUONG; IVAN KHARCHENKO; JEAN LUC AGARD; & AHMED RAZIUDDIN, MDA 65-year-old man who had HIV well-controlled with highly active antiretroviral therapy, hypertension, sciatica, and restless leg syndrome presented to the emergency department with left leg pain. He also had had chemotherapy and radiation for anal cancer. The patient said the pain had started 45 minutes earlier when he was sitting on the toilet.He described the pain as sore in quality and 10/10 on the pain scale. He reported that it had started in his lower back and radiated to his left leg. He said he had had no trauma or weakness to the regi...
Source: The Case Files - May 28, 2019 Category: Emergency Medicine Tags: Blog Posts Source Type: research

First-line diuretics versus other classes of antihypertensive drugs for hypertension
CONCLUSIONS: When used as first-line agents for the treatment of hypertension, thiazides and thiazide-like drugs likely do not change total mortality and likely decrease some morbidity outcomes such as cardiovascular events and withdrawals due to adverse effects, when compared to beta-blockers, calcium channel blockers, ACE inhibitors, and alpha-blockers.PMID:37439548 | DOI:10.1002/14651858.CD008161.pub3
Source: Cochrane Database of Systematic Reviews - July 13, 2023 Category: General Medicine Authors: Marcia Reinhart Lorri Puil Douglas M Salzwedel James M Wright Source Type: research

Interventions for preventing post-operative atrial fibrillation in patients undergoing heart surgery.
CONCLUSIONS: Prophylaxis to prevent atrial fibrillation after cardiac surgery with any of the studied pharmacological or non-pharmacological interventions may be favored because of its reduction in the rate of atrial fibrillation, decrease in the length of stay and cost of hospital treatment and a possible decrease in the rate of stroke. However, this review is limited by the quality of the available data and heterogeneity between the included studies. Selection of appropriate interventions may depend on the individual patient situation and should take into consideration adverse effects and the cost associated with each ap...
Source: Cochrane Database of Systematic Reviews - March 2, 2013 Category: Journals (General) Authors: Arsenault KA, Yusuf AM, Crystal E, Healey JS, Morillo CA, Nair GM, Whitlock RP Tags: Cochrane Database Syst Rev Source Type: research

Beta-blocker Use and Clinical Outcomes after Primary Vascular Surgery: A Nationwide Propensity Score-Matched Study
Conclusion: Beta-blocker use after primary vascular surgery was associated with a lower risk of major amputation but an increased risk of hospitalisation with MI and stroke. No associations were found between beta-blocker use and all-cause mortality or the risk of recurrent vascular surgery. However, our results are not sufficient to alter the indication for beta-blocker use among symptomatic peripheral arterial disease patients.
Source: European Journal of Vascular and Endovascular Surgery - May 8, 2013 Category: Surgery Authors: A. Høgh, J.S. Lindholt, H. Nielsen, L.P. Jensen, S.P. Johnsen Tags: Peripheral Arterial Disease Source Type: research

{beta}-Blockers and Cardiovascular Events in Patients With and Without Myocardial Infarction: Post Hoc Analysis From the CHARISMA Trial Original Articles
Conclusions— β-blocker use in patients with prior MI but no heart failure was associated with a lower composite cardiovascular outcome driven by lower risk of recurrent MI with no difference in mortality. However, β-blocker use was not associated with lower cardiovascular events in those without MI, with a suggestion of inferior outcome with regard to stroke risk. Clinical Trial Registration— URL: http://www.clinicaltrials.gov. Unique identifier: NCT00050817.
Source: Circulation: Cardiovascular Quality and Outcomes - November 18, 2014 Category: Cardiology Authors: Bangalore, S., Bhatt, D. L., Steg, P. G., Weber, M. A., Boden, W. E., Hamm, C. W., Montalescot, G., Hsu, A., Fox, K. A. A., Lincoff, A. M. Tags: Secondary prevention Original Articles Source Type: research

Prevalence of atrial fibrillation in an urban population in India: the Nagpur pilot study
Conclusions The prevalence of AF was low compared with other regions of the world and stroke prophylaxis was underused. A larger study is needed to confirm these findings. This study demonstrates that larger evaluations would be feasible using the community-based techniques employed here.
Source: Heart Asia - April 17, 2016 Category: Cardiology Authors: Saggu, D. K., Sundar, G., Nair, S. G., Bhargava, V. C., Lalukota, K., Chennapragada, S., Narasimhan, C., Chugh, S. S. Tags: Original research Source Type: research

Selective Heart Rate Reduction With Ivabradine Increases Central Blood Pressure in Stable Coronary Artery Disease Clinical Trials
In conclusion, the decrease in HR with ivabradine was associated with an increase in central systolic pressure, which may have antagonized possible benefits of HR lowering in coronary artery disease patients. Clinical Trials—URL: http://www.clinicaltrials.gov. Unique identifier NCT01039389.
Source: Hypertension - May 10, 2016 Category: Cardiology Authors: Rimoldi, S. F., Messerli, F. H., Cerny, D., Gloekler, S., Traupe, T., Laurent, S., Seiler, C. Tags: Hemodynamics, Hypertension, Coronary Artery Disease Clinical Trials Source Type: research

Secondary CV Prevention in South America in a Community Setting: The PURE Study
ConclusionsThere are large gaps in the use of proven medications for secondary prevention of cardiovascular disease in South America. Strategies to improve the sustained use of these medications will likely reduce cardiovascular disease burden substantially.
Source: Global Heart - July 5, 2018 Category: Cardiology Source Type: research